First Manhattan’s Arcturus Therapeutics ARCT Stock Holding History

First Manhattan’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-200	Closed	-$2K	–	1690
2022 Q3	$2K	Hold	200	–	–	﹤0.01%	1409
2022 Q2	$3K	Hold	200	–	–	﹤0.01%	1395
2022 Q1	$5K	Hold	200	–	–	﹤0.01%	1374
2021 Q4	$7K	Hold	200	–	–	﹤0.01%	1323
2021 Q3	$9K	Hold	200	–	–	﹤0.01%	1291
2021 Q2	$6K	Hold	200	–	–	﹤0.01%	1350
2021 Q1	$8K	Buy	+200	New	+$11.9K	﹤0.01%	1260
2020 Q2	–	Sell	-5,000	Closed	-$67K	–	1375
2020 Q1	$67K	Buy	+5,000	New	+$64K	﹤0.01%	794

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

First Manhattan's ARCT Position: Q4 2022 in Review

First Manhattan sold out of Arcturus Therapeutics (ARCT) in Q4 2022, closing a stake of 200 shares — an estimated $2K sold.

First Manhattan first reported a position in ARCT in Q1 2020 and held it in 8 quarters. The position peaked at $67K in Q1 2020. 111 funds tracked by Wall St. Rank hold ARCT as of Q4 2022.

First Manhattan reported no remaining Arcturus Therapeutics position as of Q4 2022 after selling out during the quarter.
First Manhattan sold 200 Arcturus Therapeutics shares in Q4 2022, an estimated $2K.
First Manhattan first reported a position in Arcturus Therapeutics in Q1 2020 and held it in 8 quarters.
First Manhattan's Arcturus Therapeutics position peaked at $67K in Q1 2020.
111 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2022.

Based on First Manhattan's 13F filing for Q4 2022, filed 14 Feb 2023.